Methylsulfonylmethane Increases the Alveolar Bone Density of Mandibles in Aging Female Mice

Hanan Aljohani1,2, Linda T. Senbanjo1, Mohammed Al Qranei1,3, Joseph P. Stains4 and Meenakshi A. Chellaiah1*

1 Department of Oncology and Diagnostic Sciences, School of Dentistry, University of Maryland, Baltimore, Baltimore, MD, United States, 2 Department of Oral Medicine and Diagnostics Sciences, School of Dentistry, King Saud University, Riyadh, Saudi Arabia, 3 Department of Preventive Dental Sciences, School of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, 4 Department of Orthopedics, University of Maryland School of Medicine, Baltimore, MD, United States

Methylsulfonylmethane (MSM) is a naturally occurring anti-inflammatory compound that effectively treats multiple degenerative diseases such as osteoarthritis and acute pancreatitis. Our previous studies have demonstrated the ability of MSM to differentiate stem cells from human exfoliated deciduous (SHED) teeth into osteoblast-like cells. This study examined the systemic effect of MSM in 36-week-old aging C57BL/6 female mice in vivo by injecting MSM for 13 weeks. Serum analyses showed an increase in expression levels of bone formation markers [osteocalcin (OCN) and procollagen type 1 intact N-terminal propeptide (P1NP)] and a reduction in bone resorption markers [tartrate-resistant acid phosphatase (TRAP) and C-terminal telopeptide of type I collagen (CTX-I)] in MSM-injected animals. Micro-computed tomographic images demonstrated an increase in trabecular bone density in mandibles. The trabecular bone density tended to be higher in the femur, although the increase was not significantly different between the MSM- and phosphate-buffered saline (PBS)-injected mice. In mandibles, an increase in bone density with a corresponding decrease in the marrow cavity was observed in the MSM-injected mice. Furthermore, immunohistochemical analyses of the mandibles for the osteoblast-specific marker – OCN, and the mesenchymal stem cell-specific marker – CD105 showed a significant increase and decrease in OCN and CD105 positive cells, respectively. Areas of bone loss were observed in the inter-radicular region of mandibles in control mice. However, this loss was considerably decreased due to stimulation of bone formation in response to MSM injection. In conclusion, our study has demonstrated the ability of MSM to induce osteoblast formation and function in vivo, resulting in increased bone formation in the mandible. Hence, the application of MSM and stem cells of interest may be the right combination in alveolar bone regeneration under periodontal or other related diseases that demonstrate bone loss.

Keywords: osteoblasts, aging mice, bone formation, osteoclasts, methylsulfonylmethane
INTRODUCTION

Bone loss associated with osteoporosis represents a significant health care problem, and it is related to increased activation of osteoclast bone resorption function (Mundy, 2007; Khosla et al., 2012; Soysa and Alles, 2016; Cai et al., 2017). Many contributing factors can cause osteoporosis, and one such aspect is aging (Demontiero et al., 2012). Increased pro-inflammatory markers in older adults represent aging-related osteoporosis (Weitzmann and Pacifici, 2006; Pacifici, 2008). Increased inflammation in aged mammals is correlated with higher circulating pro-inflammatory cytokines than young adults (Abdelmagid et al., 2015). The reason is that increased circulating pro-inflammatory mediators could induce molecular changes in the periodontal tissue and exaggerate bone loss in older adults (Liang et al., 2010). In addition, tooth loss in older adults is linked with periodontal disease (Koduganti et al., 2009).

Experiments with animals and studies with humans have implicated pro-inflammatory cytokines (e.g., interleukin-1, tumor necrosis factor-alpha, and interleukin-6) as primary mediators of physiologic and pathologic bone remodeling (Goldring, 2003). Chronic inflammation in aging is specified by increased inflammatory mediators, osteoclast activation, and bone loss. Furthermore, aging leads to underlying modifications in the differentiation of mesenchymal stem cells (MSCs) and therefore impaired osteoblast differentiation and bone formation (Abdelmagid et al., 2015). The deregulation of the balance between bone formation and bone resorption causes age-related osteoporosis. The deregulation is related to increase osteoclast formation and bone resorption and decrease osteoblast differentiation and bone formation. Appropriate alteration of the inflammatory condition is required for typical bone remodeling. Therefore, it is essential to identify a new anti-inflammatory agent to increase osteoblast function and bone formation.

Methylsulfonylmethane (MSM) is a naturally occurring organosulfur compound with several health benefits. It is a potent anti-inflammatory compound, which reduces chronic inflammation and relieves pain. It is used as a dietary supplement with glucosamine and chondroitin sulfate to treat arthritis (Usha and Naidu, 2004; Kim et al., 2006; Gregory et al., 2008; Lubis et al., 2017). An increase in pro-inflammatory cytokines (e.g., IL-6 and TNF-α) has been observed due to activation of the transcriptional factor NF-κB. It is worth noting that MSM reduced the expression of these cytokines by inhibiting NF-κB activity (Kim et al., 2009; Ahn et al., 2015). Moreover, MSM is a selective inhibitor of the NLRP3 inflammasome activation in human macrophages in vitro; analyses in mice corroborated this observation in vivo (Ahn et al., 2015).

Studies by others and we elucidated MSM’s effect on bone formation using stem cells such as MSCs, human periodontal ligament stem cells (hPDLSCs), and stem cells from human exfoliated deciduous teeth (SHED) (Joung et al., 2012; Aljohani et al., 2019; Ha and Choung, 2020). MSM induces osteoblast differentiation via activating the JAK2/STAT5b pathway in MSCs (Joung et al., 2012). We found that MSM significantly increases transglutaminase-2 (TG-2) activity and its interaction with extracellular matrix (ECM) proteins such as collagen type 1 and osteopontin (Aljohani et al., 2019). An increase in the expression of osteogenic markers and mineralization by MSM in PDLSCs and SHED suggests that MSM is suitable not only for the inhibition of inflammatory-related events (Kim et al., 2009; Ahn et al., 2015) and diseases but also for increasing bone formation (Joung et al., 2012; Aljohani et al., 2019; Ha and Choung, 2020). In vivo analysis with hPDLSCs in calvarial defect and transplantation models indicate that MSM could be used with stem cells for bone regeneration in vivo (Ha and Choung, 2020). Mice naturally develop accelerated periodontal bone loss as a function of age (Liang et al., 2010). In addition, aging can cause bone loss in trabecular bone microarchitecture, leading to bone fracture and tooth loss (Huttner et al., 2009; Koduganti et al., 2009; Willingham et al., 2010; Eastell et al., 2016). Thus, we believed that the aging mouse model represents a genuinely chronic model to study possible periodontal tissue loss and restoration or remodeling mechanisms. Therefore, we proceeded to identify the effect of MSM on bone formation by osteoblasts in the aging mouse model. Here, we aim to relate the influence of MSM on the trabecular bone density of the femoral head to the mandible. Female C57BL/6 mice at 36 weeks of age were used for aging-related studies (Jilka, 2013). Histological and immunohistochemical analyses demonstrated that MSM could be an applicable osteogenic element in treating bone loss under inflammation, including aging and post-menopausal osteoporosis conditions.

MATERIALS AND METHODS

Osteoblast Studies

Cell Culture

MC3T3-E1 (mouse mesenchyme stem cells) and UMR-106 (rat osteoblast-like cells) were obtained from American Type Culture Collection (ATCC, Manassas, VA, United States). SHED were a kind gift from Dr. Jacques Nör (University of Michigan, Ann Arbor, MI, United States). Briefly, SHED were collected from exfoliated deciduous incisors of 7- to 8-year-old children. Guidelines set and approved by the National Institutes of Health Office of Human Subjects Research were followed during the isolation procedure (Bento et al., 2013). Briefly, the pulp from a remnant crown was digested in a solution containing 3 mg/ml collagenase type I and 4 mg/ml dispase (Worthington Biochem, Freehold, NJ, United States and Roche Molecular Biochemicals, Pleasanton, CA, United States) for 1 h at 37°C. After digestion, the solution was passed through a 70-µm strainer (Falcon) to obtain a single-cell suspension as described (Gronthos et al., 2000).

UMR-106 cells were cultured in DMEM media containing 10% FBS, 1% penicillin/streptomycin, and 0.05% Gentamicin. In contrast, MC3T3-E1 cells and SHED were maintained in α-minimal essential medium (MEM) with 10% fetal bovine serum and 1% penicillin/streptomycin. All cells were maintained at 37°C in 5% CO₂, and the media was changed every 3 days. For osteogenic differentiation, cells were incubated
with osteogenic medium (OM), consisting of osteogenic factors, such as 50 μM ascorbic acid, 5 mM β-glycerophosphate, and 0.05% Gentamicin. In addition, some cultures were treated with MSM in the basal medium (BM) with no osteogenic factors.

**Alkaline Phosphatase Activity Analysis**

Alkaline phosphatase (ALP) activity was measured using the colorimetric assay (Aljohani et al., 2019). Cells were seeded in a six-well plate in MSM (20 mM) presence or absence for 7 days, and lysates were made as described (Aljohani et al., 2019). An equal amount of protein was used in triplicates in a 96-well plate to measure the activity. The absorbance was measured (405 nm) in a microplate reader (Cytation3 image) with integrated imaging software (Gen5 version 2.09) after the addition of p-nitrophenyl phosphate (10 μl; Sigma, St. Louis, MO, United States) to each well.

**Alizarin Red S Staining and Von Kossa Staining**

UMR-106 cells seeded and incubated for 7 days in a six-well plate in the presence and absence of MSM (20 mM) were used to determine the effect of MSM on matrix mineralization. Cells without any MSM but grown in the OM were used as controls. Alizarin red S (ARS) is used to stain cells after washing with phosphate-buffered saline (PBS) three times. Absolute ethanol was used to fix the cells for 30 min at room temperature. After ethanol aspiration, 2% ARS solution was added to each well and processed as described previously (Aljohani et al., 2019). For Von Kossa staining, cells were washed with PBS three times and fixed with 10% paraformaldehyde for 10 min at room temperature. After the aspiration of fixative and washing with PBS, a 5% silver nitrate solution was used as described previously (Aljohani et al., 2019). Scanning the culture plates stained for ARS and Von Kossa was done in the scanner (EPSON perfection V200). Nikon Eclipse TE 2000-inverted light microscope were used to obtain magnified images (10× objective).

**Animals and Experimental Procedures**

Thirty-six-week-old female C57BL6 mice weighing an average of 30 g were obtained from Charles River (MD, United States). Mice were maintained in the animal facility at the University of Maryland, Baltimore (School of Dentistry) animal care facility at room temperature (21 ± 1°C), with a 12 h light/12 h dark cycle. Pelleted mouse diet was fed *ad libitum*, and the mouse had free access to water. IACUC of the University of Maryland, Baltimore reviewed and approved the experimental procedures (approval number #417006, MD, United States). All experiments were performed under the relevant guidelines and regulations.

The mice were kept in the facility for a week for acclimatization before the injection. Mice were divided at random into two groups: a control group, injected with PBS (*n* = 6) as Group-1, and MSM injected mice (*n* = 6) as Group-2. Methylsulfonylmethane (PFR1346-1G, Sigma, St. Louis, MO, United States) was dissolved in PBS and injected subcutaneously (100 mg/kg) in a final volume of 100 μl. The injections were administered three times (i.e., alternate days) per week for 13 weeks. The animal weight was recorded every 4 weeks at the initial phase for 8 weeks and then after 3 and 2 weeks until the sacrifice time at 13 weeks. The mice were 49 weeks old at the time of sacrifice. Soft organs such as the heart, kidney, and liver have been isolated, and histological sections were prepared to assess any abnormalities caused by injections in these organs. Histological sections of these organs were stained with hematoxylin and eosin (H&E). Aperio ScanScope CS System (Vista, CA, United States) was used to scan the histological sections (bone and other tissues) (Aljohani et al., 2021). The assessment was performed blindly by a pathologist.

**Bone Histology and Histomorphometry Analysis**

Bone histomorphometry analysis was performed as described previously (Chellaiah et al., 2003; Aljohani et al., 2021). The tibia and mandibles were stained with H&E and tartrate-resistant acid phosphatase (TRAP) staining according to the manufacturer’s protocols (Sigma, St. Louis, MO, United States). Stained sections were scanned and analyzed using the Aperio ScanScope CS instrument (Aperio Scanscope CS system, Vista, CA, United States). The number of TRAP-positive osteoclasts and cuboidal osteoblasts adherent to the bone surface were counted using the Fiji (ImageJ) software.

**Immunohistochemistry Analyses in Bone Sections**

Immunohistochemistry was performed as described (Gupta et al., 2012). After blocking the sections with the blocking solution (2.5% BSA or horse serum in PBS) for 60 min, at 4°C, the slides were incubated overnight at 4°C with the primary antibody (Abcam, Cambridge, MA, United States) of interest [e.g., OCN (rabbit polyclonal), or CD105 (Mouse monoclonal)] which was diluted (1:100) in blocking solution. After washing with PBS, the sections were then incubated with the corresponding secondary antibodies for 60 min. The slides were then washed and developed as previously described (Gupta et al., 2012). Finally, immunostained sections were scanned using an Aperio Scanscope CS instrument (Aperio Scanscope CS system, Vista, CA, United States).

**Microcomputed Tomography Analysis**

The femurs and mandibles were dissected from mice, and the soft tissues from the bones were removed. Bones were fixed in 4% paraformaldehyde for 2 days and then washed with PBS. Subsequently, bones were wrapped with gauze soaked in PBS and kept at 4°C. Three-dimensional microcomputed tomography (micro-CT) was performed on the femurs and mandibles (*n* = 6) using a Bruker SkyScan 1172 micro-CT scanner (Carteret, NJ, United States). Specimens were scanned with a 20 K resolution, 10 μm voxel size, 0.5 Al filter at 55 kV, and 167 μA, as described previously (Moorer et al., 2017). Bone morphology and microarchitecture were assessed at the distal femoral metaphysis in a region of interest (ROI) chosen for a range of 0.2–2.0 mm proximal to the
distal femoral growth plate. For the mandibles, the ROI was selected in the inter-radicular area of the first molar. The skeletal parameters assessed by micro-CT followed published nomenclature guidelines (Dempster et al., 2013).

Enzyme-Linked Immunosorbent Assay
Serum was separated from blood samples and frozen at −80°C until use. Serum markers of bone resorption (TRAP); (C-terminal telopeptide of type I collag, CTX-I) and of bone formation (osteocalcin, OCN); (procollagen type I intact N-terminal propeptide, PINP), were measured in duplicate using enzyme-linked immunosorbent assay (ELISA) kits (Immunodiagnostics Systems, and LS-Bio Systems) according to the manufacturer’s instructions. In addition, serum calcium levels were also measured using a calcium detection kit (Biovision, Inc., Milpitas, CA, United States).

Osteoclast Studies
Differentiation of Osteoclasts From RAW 264.7 Macrophage-Like Cell Line
Recombinant GST-RANKL was purified as described previously (Ma et al., 2010). Osteoclasts were generated from RAW 264.7 (ATCC® TIB-71™) cells as described (AlQranei et al., 2020). Mature multinucleated osteoclasts were observed from day three onward and used for various analyses.

Tartrate-Resistant Acid Phosphatase-Staining
For TRAP staining, undifferentiated macrophages were gently removed with a cell stripper solution, and multinucleated osteoclasts attached to the culture plates were used for staining as described previously (AlQranei et al., 2020). In brief, osteoclasts were fixed with 4% paraformaldehyde and washed three times with PBS. TRAP staining was done using the Leukocyte Acid Phosphatase Kit as described in the manufacturer’s protocol. Stained cells were photographed, and the number of mature osteoclasts was measured using Cytation5 image reader with software (Gen5 version 2.09).

Dentine Resorption Assay
Dentine slices were processed as described previously (Chellaiah et al., 2000). After processing, dentine slices were incubated overnight at 37°C in a serum-free α-MEM medium. The next day, an osteoclast suspension containing 2 × 10⁴ cells was gently added to the dentine slices. After adherence for 2 h, the culture media were replaced with serum-containing α-MEM containing RANKL with or without MSM at different concentrations (20 and 40 mM). After incubation for 48 h, dentine slices were processed and stained with acid hematoxylin (Sigma, St. Louis, MO, United States) for 6 min and washed well with water. Images of resorption pits were captured using a Nikon Eclipse TE 2000 inverted light microscope using a 20× and 40× objective (24).

Statistical Analysis
All data are presented as mean ± SEM. Student’s t-test or Mann–Whitney U test was used to determine the statistical significance (Graph Pad Software, Graph Pad Inc., San Diego, CA, United States). The p-value < 0.05 is considered statistically significant.

RESULTS
Analysis of the Effect of Methylsulfonylmethane on Bone Mineralization in vitro
To demonstrate the effect of MSM on ALP activity, we used MC3T3-E1 and UMR-106 osteoblastic cell lines. Consistent with the observation shown in SHED (Aljohani et al., 2019), MSM increased ALP activity in these cells in the basal growth medium (BM) in vitro. This increase was equivalent to an OM containing osteogenic factors (Supplementary Figure 1).

Effects of Subcutaneous Injection of Methylsulfonylmethane on Body Weight Measurements and Soft Organs
We subsequently sought to determine the effect of MSM on bone formation in vivo using an aging mouse model. The injection was performed for 13 weeks, as described in section “Materials and Methods.” During the injection period, the mice looked healthy and exhibited normal behavior. Some mice exhibited hair loss when they first arrived at our facility. However, after 6 weeks of injection with MSM, these mice displayed hair growth compared to the PBS-injected control group. At the end of the injection period of 13 weeks, the mice injected with PBS demonstrated hair loss patches (Supplementary Figure 2A, white arrows) compared to the MSM group. The hair loss was reduced, and hair growth was observed in MSM injected group (Supplementary Figure 2A). No severe abnormalities were observed in the mice injected with PBS or MSM at the end of the injection period. It was also observed that MSM did not affect body weight changes compared to the PBS-injected mice (Supplementary Figure 2B). In histological sections, all soft organs (heart, kidney, and liver) showed normal histology with no signs of damage, inflammation, or defects (Supplementary Figure 3).

Depiction of the Region of Interest Chosen for Microcomputed Tomography Analyses in Femoral and Mandibular Bones
A two-dimensional (2D) model of the bones dissected from the injected mice was performed using the micro-CT. The ROI used in the femur and mandible is shown in Figure 1. In the femur, the chosen ROI for the trabecular bone lies below the growth plate region (i.e., in the metaphyseal area), where the cancellous or trabecular bones are present. In the mandible, the ROI was chosen in the inter-radicular area between the first molar roots. As depicted in Figure 1A, blue brackets in the femur and squares inside the sagittal (Figure 1B) and coronal (Figure 1C) sections indicate the ROI for scanning in micro-CT.
Bone of the mandibles showed a considerable increase in BV/TV, Methylsulfonylmethane (MSM) Phosphate-Buffered Saline and the Mandible From Mice Injected With Microcomputed Tomography Analyses in controls. There were no significant changes in the bone density or spacing (Tb. S) in mice injected with MSM compared with PBS-injected controls. Although trabecular number (Tb. N) was higher in the MSM-treated mice than the control mice, no significant differences were noted in the number of trabecular bone or its density. These observations suggest that MSM can systematically induce bone formation, but its effects are more prominent in the bones in the mandibular region than in the long bones.

**Morphometric Analysis of the Tibial and Mandibular Bone Sections**

Methylsulfonylmethane injection appears to have increased the Tb. N in MSM-injected mice (Figures 4B, B′, B″) compared with PBS-injected mice (Figures 4A, A′, A″). As detected by the micro-CT morphometry analyses, static histomorphometric measurements exhibited no significant femoral Tb. N or density changes in mice injected with MSM (Figure 2) compared to the control mice. An increase was also observed in the inter-radicular bone of the mandible. These observations suggest that MSM can systematically induce bone formation, but its effects are more prominent in the bones in the mandibular region than in the long bones.

**Immunohistochemistry Analyses With Osteocalcin and CD105 Antibody**

We then used the mandible sections for immunohistochemistry analyses with OCN, a biomarker for osteoblast activity, and CD105, a stem cell marker. Immunostained sections demonstrated an increase in bone density in the inter-radicular bone region of the mandible with a significant rise in OCN-positive bone cells and a decline in CD105 positive stem cells in MSM injected mice (Figures 6B, B′, C, D). In addition, as compared with PBS-injected mice (Figures 6A, A′), the inter-radicular bone width (IRB) is more in MSM injected mice (Figures 6B, B″). Thus, these observations indicate that MSM...
increases bone formation and the differentiation of CD105 positive stem cells into OCN-positive osteoblast-like cells.

**Analysis of Serum Biomarkers for Bone Formation and Resorption by Enzyme-Linked Immunosorbent Assay**

Serum was analyzed by ELISA for bone resorption (TRAP and CTX-I) and bone formation (OCN, P1NP) markers (Figure 7). An increase in osteoblast markers such as OCN and P1NP was observed in mice injected with MSM compared to PBS-injected mice (Figures 7B,D). Interestingly, we also detected a notable decrease in the levels of TRAP and CTX-I in the MSM-injected mouse group as compared to the control group, which suggests that osteoclast activity may be reduced by MSM (Figures 7A,C) even though the osteoclast number was not significantly different between PBS- and MSM-injected mice (Figure 5C).

**DISCUSSION**

Our previous studies have shown that MSM influences the differentiation of SHED into osteoblast-like cells and their osteogenic potential. In SHED, TG-2 enzyme is involved in the cross-linking of ECM proteins (collagen and osteopontin) and the mineralization process in vitro in the presence of MSM (Aljohani et al., 2019). MC3T3 and UMR-106 cells are commonly used for in vitro studies. Validating the results of our earlier studies in SHED (Aljohani et al., 2019), here we showed that MSM increased ALP activity and mineralization in UMR-106 cells. Furthermore, besides MC3T3, SHED, and UMR-106 cells, MSM also increased the expression levels of osteogenic specific markers (ALP, osteopontin, OCN, RUNX2, and osterix) in hPDLCs (Ha and Choung, 2020). We experimented with aging mice to comprehend whether in vitro findings of increased bone formation by MSM in vitro are also relevant in vivo. We performed a series of observations in aging mice, especially in the mandibular bone area, to elucidate whether MSM is an attractive therapeutic compound for the treatment of bone loss.

Bone loss occurs under conditions of periodontitis and osteoporosis, and both progress with increasing age (Jonasson and Rythen, 2016). Most clinical studies on the effects of human aging on periodontal tissues suggest a significant correlation between the aging and incidence of periodontal disease (Papapanou et al., 1989; Ismail et al., 1990; Haffajee et al., 1991; Huttner et al., 2009). MSM is commonly used as a supplement to treat arthritis and other inflammatory conditions.
Aging itself has been considered a chronic inflammatory state (Gibon et al., 2017). Periodontal tissues of aged mice have increased inflammation and elevated alveolar bone loss compared to young mice (Liang et al., 2010). Therefore, we used the aging mice model to identify the effect of MSM on bone cells. Mice were injected with MSM subcutaneously for 13 weeks. Our study demonstrated more bone loss in control mice which is diminished in MSM injected mice in the mandibular region.

We then did a series of studies in aging mice and analyzed the bone by micro-CT and histomorphometry analyses. We determined the quantitative differences in PBS- and MSM-injected mice by measuring BV/TV, Tb. Th, trabecular spacing, and Tb. N. Although bone loss was observed in both long bones and mandibular bones due to aging in PBS-injected mice, bone formation by MSM was more significant in the mandibular bones than in long bones. Since MSM is an anti-inflammatory compound, injection of MSM may have reduced the inflammatory events in the mandibular area and improved bone density. Clark et al. reported depletion of macrophages in old mice resulted in decreased inflammatory cytokines within the gingiva and reduced bone loss (Clark et al., 2021).

Furthermore, as suggested by others, it may be due to the unique characteristics of collagen in the mandible compared to the long bones (Matsuura et al., 2014). The uniqueness may include a more significant amount of collagen with a smaller amount of mature cross-links and a lower extent of Lysine hydroxylation. These structures support the mandibular matrix’s distinct interactions with bone remodeling cells, including osteoblasts, osteoclasts, and precursors (Matsuura et al., 2014). Moreover, the differentiation of osteoblasts occurs in optimal collagen cross-linking (Turecek et al., 2008). Studies have also shown that proteinases used for bone resorption in mandible displayed different properties from long bones (Azari et al., 2011; de Souza Faloni et al., 2011; Vermeer et al., 2013). Furthermore, the bone formation rate decreases with age in femoral bones, whereas it remains elevated in the jawbones (Huja and Beck, 2008). Nevertheless, irrespective of the mechanism, it is possible that the arrangement of collagen in mandibular bone may assist in bone remodeling via their interaction with bone remodeling cells. Therefore, the collagen matrix structure and its interaction with bone cells in the mandible may provide a notable difference in the remodeling process compared with long bones.

Studies have shown that inter-radicular bone loss is associated with the progression of bone loss in multirooted teeth in patients with chronic periodontitis (Desai and Shinde, 2012). Inter-radicular alveolar bone is exposed to occlusal stimuli and is often used for alveolar bone histomorphometry. Here, in the TRAP-stained mandibular bone sections, we have shown a significant bone loss in the inter-radicular bone region of PBS-injected mice (Figures 5A,A’); however, although the osteoclast number remains the same in both PBS- and MSM-injected mice, a considerable decrease in the bone loss was observed in MSM-injected mice (Figures 5B,B’).

In vitro experiments with
osteoclasts also demonstrated no changes in osteoclast number in MSM untreated or treated osteoclasts. We then raised the question, Is this related to an increase in bone formation?

To further determine that MSM stimulated bone formation, we analyzed the serum for bone resorption (TRAP and CTX-1) and formation (OCN and P1NP) markers. Although MSM did not affect the bone resorption of osteoclasts from RAW cells in vitro, a significant decrease in the bone resorption markers was observed in the serum of mice injected with MSM compared with PBS-injected mice. The levels of TRAP and CTX1 represent the measurement of enzymes and peptides released during bone resorption. As indicated by others (Milne et al., 2009), serum phosphatase levels (TRAP) can be used as an alternative measure to validate osteoclast activity. We found that MSM can reduce bone resorption. The measurement of serum levels of P1NP is precisely comparative to the amount of new collagen produced by osteoblasts. Osteocalcin level is a valid marker of bone formation and represents osteoid formation rather than mineralized bone formation. Both P1NP and OCN are currently the best and widely used indicators of bone formation (Melkko et al., 1996; Huja and Beck, 2008; Chavassieux et al., 2015). In addition to reducing bone resorption by osteoclasts, an increase in bone formation by osteoblasts may have contributed to the rise in bone density in the inter-radicular bone region of the bone.

Consistent with an increase in serum levels of OCN, immunohistochemistry analyses also displayed more OCN-positive cells in the mandibular area. The intriguing observation in the immunohistochemistry analyses is a decrease in CD105 positive cells and a corresponding increase in OCN-positive cells in the mandibular bone sections of MSM-injected mice. Several types of stem cells (DPSCs, SHED, PDLSCs, SCAPs, and DFPCs) are present in the dental tissue (Gronthos et al., 2000; Sonoyama et al., 2006, 2008; Morsczeck et al., 2009; Morsczeck and Schmalz, 2010; Morsczeck, 2015), and these stem cells can provide novel therapies in dentistry and support bone formation in vitro and in vivo. The expression of CD105 (aka endoglin)
in MSC is necessary for self-renewal. These cells are shown to form bone in vivo and are a promising tool for bone regeneration (Aslan et al., 2006). A decrease in CD105 positive cells and a corresponding increase in OCN-positive osteoblast-like cells in MSM-injected mice strongly suggest that MSM can induce osteogenic differentiation of stem cells in vivo. Future studies will...
evaluate the mechanism and potential of CD105 positive cells to differentiate into osteoblast-like cells in the presence of MSM.

We showed in this study the initial characterization of the effects of MSM on bone formation in aging mice. Yet, we recognize that this study has limitations, and our future studies will address these limitations. More specifically, our further investigation includes analyzing the effects of MSM on: (1) bone formation using dynamic histomorphometry as shown previously (Jilka et al., 1996; Weinstein et al., 1997; Chellaiah et al., 2000) and (2) the differentiation of CD105 positive cells into OCN-positive osteoclast-like cells in vitro and in vivo. In vitro analysis will also focus on the molecular mechanisms by which MSM induces the osteogenic differentiation of stem cells (SHED) and increases bone formation. For example, is there any role for the Wnt pathway to stimulate the differentiation of SHED into osteoblast-like cells and bone formation?

**CONCLUSION**

Based on histomorphometry, micro-CT, biochemical, and immunohistochemistry analyses, we have found that MSM increases bone formation in the inter-radicular region of the mandible of the aging mice. Furthermore, OCN-positive osteoblast-like cells were more in the inter-radicular areas of bone, where more bone density was observed. A decrease in CD105 positive stem cells with a concomitant increase in osteoblast-like cells suggests that MSM can induce the differentiation process in vivo based on the needs. Although these findings additionally support the bone remodeling effect of MSM, more studies are necessary to identify the molecular mechanisms involved in this differentiation process in vitro and in vivo. We suggest that the therapeutic effect of MSM on bone loss could go beyond alveolar bone loss that occurs in periodontitis. Studies have shown that estrogen loss promotes continual inflammation, which supports post-menopausal osteoporosis (PMO). Pro-inflammatory cytokines (e.g., TNF-alpha and IL-17A) contribute to osteoclast activation and bone loss in PMO. Thus, the potent anti-inflammatory MSM can be used as a therapeutic agent to improve bone loss-associated diseases, including periodontitis, PMO, and rheumatoid arthritis.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
ETHICS STATEMENT

The experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Maryland, Baltimore (approval number #417006, MD, United States). All experiments were performed under the relevant guidelines and regulations.

AUTHOR CONTRIBUTIONS

MC and HA were involved in the conceptualization, data curation, and formal analyses. HA performed the injections and maintained the animals. She also collected the tissues (blood, liver, heart, kidney, and bones) for various studies and serum to analyze biomarkers for bone resorption and bone formation by ELISA. LS and MA performed IHC staining and osteoclast studies, respectively. HA and JS conducted micro-CT scanning, data analyses, and computations. MC also completed funding acquisition, project administration, resources, supervision, validation, and writing the original draft. All authors contributed to the article and approved the submitted version.

REFERENCES

Abdelmagid, S. M., Barbe, M. F., and Safadi, F. F. (2015). Role of inflammation in the aging bones. Life Sci. 123, 25–34. doi: 10.1016/j.lfs.2014.11.011
Ahn, H., Kim, J. D., Lee, J. M., Kim, Y. J., Cho, Y. W., and Lee, G. S. (2015). Methylsulfonylmethane inhibits NLRP3 inflammasome activation. Cytokine 71, 223–231. doi: 10.1016/j.cyto.2014.11.001
Aljohani, H., Senbanjo, L. T., and Chellaiah, M. A. (2019). Methylsulfonylmethane increases osteogenesis and regulates the mineralization of the matrix by transglutaminase 2 in SHED cells. PLoS One 14:e0225598. doi: 10.1371/journal.pone.0225598
Aljohani, H., Stains, J. P., Majumdar, S., Srinivasan, D., Senbanjo, L., and Chellaiah, M. A. (2020). C-phycocyanin attenuates RANKL-induced osteoclastogenesis and bone resorption in vitro through inhibiting ROS levels, NFATc1 and NF-kappaB activation. Sci. Rep. 10:2513. doi: 10.1038/s41598-020-59363-y
Aslan, H., Zilberman, Y., Kandel, L., Liebergall, M., Oskouian, R. J., Gazit, D., et al. (2006). Osteogenic differentiation of noncultured immunoisolated bone Marrow-Derived CD105+ cells. Stem Cells 24, 1728–1737. doi: 10.1634/stemcells.2005-0546
Azari, A., Schoenmaker, T., de Souza Faloni, A. P., Everts, V., and de Vries, T. J. (2017). Methylsulfonylmethane: histomorphometry in 370 postmenopausal women? J. Clin. Endocrinol. Metab. 100, 4662–4668. doi: 10.1210/jc.2015-2957
Chellaiah, M. A., Kizer, N., Silva, M., Alvarez, U., Kwiatkowski, D., and Huska, K. A. (2000). Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J. Cell Biol. 148, 665–678.
Chellaiah, M. A., Kizer, N., Biswas, R., Alvarez, U., Strauss-Schoenberger, J., Rifas, L., et al. (2003). Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol. Biol. Cell 14, 173–189.
Clark, D., Halpern, B., Mclau, T., Nakamura, M., Kapila, Y., and Marcucio, R. (2021). The contribution of macrophages in old mice to periodontal disease. J. Dent. Res. [Online ahead of print] 220345211009463. doi: 10.1177/00220345211009463
de Souza Faloni, A. P., Schoenmaker, T., Azari, A., Katchburian, E., Cerri, P. S., de Vries, T. J., et al. (2011). Jaw and long bone marrows have a different osteoclastogenic potential. Calcif Tissue Int. 88, 63–74. doi: 10.1007/s00223-010-9418-4
Demontiero, O., Vidal, C., and Duque, G. (2012). Aging and bone loss: new insights for the clinician. Ther. Adv. Musculoskelet. Dis 4, 61–76. doi: 10.1177/1759720X11430858
Dempster, D. W., Compston, J. E., Dreznner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., et al. (2013). Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 28, 2–17. doi: 10.1002/jbmr.1805
Desai, S., and Shinde, H. (2012). Correlation of interdental and interradicular bone loss in patients with chronic periodontitis: a clinical and radiographic study. Nigerian J. Clin. Practice 15, 125–131. doi: 10.4103/1119-3077.9 7280
Eastell, R., O’Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., et al. (2016). Post-menopausal osteoporosis. Nat. Rev. Dis. Primers 2:16069. doi: 10.1038/nrdp.2016.69
Gibson, E., Lu, Y. Y., Nathan, K., and Goodman, S. B. (2017). Inflammation, ageing, and bone regeneration. J. Orthop. Translat. 10, 28–35. doi: 10.1016/j.jot.2017.04.002
Goldring, S. R. (2003). Inflammatory mediators as essential elements in bone remodeling. Calcif Tissue Int. 73, 97–100. doi: 10.1007/s00223-002-1049-y
Gregory, P. J., Sperry, M., and Wilson, A. F. (2008). Dietary supplements for osteoarthritis. Am. Fam. Physician 77, 177–184.

FUNDING

The National Institutes of Health supported the research reported in this publication (NIH) grants under Award Number R01 AR066044 to MC.

ACKNOWLEDGMENTS

We thank Crystal Idleburg (Research Specialist, Washington University School of Medicine, Orthopedic Surgery Research, St. Louis, MO, United States) for assistance with the decalcification, sectioning, and staining (H&E and TRAP) of long bones and mandibles. In addition, we would like to thank Editage (http://www.editage.com) for editing and reviewing this manuscript for the English language.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys.2021.708905/full#supplementary-material
Moorer, M. C., Hebert, C., Tomlinson, R. E., Iyer, S. R., Chason, M., and Stains, J. P. (2017). Defective signaling, osteoblastogenesis and bone remodeling in a mouse model of connexin 43 terminal truncation. J. Cell Sci. 130, 531–540. doi: 10.1242/jcs.197283

Morsczeck, C. (2015). Molecular mechanisms in dental follicle precursor cells during the osteogenic differentiation. Histol. Histopathol. 30, 1161–1169. doi: 10.14670/HH-11-634

Morsczeck, C., Frerich, B., and Driemel, O. (2009). Dental stem cell patents. Recent Pat. DNA Gene Seq. 3, 39–43. doi: 10.2174/187221509787326200

Morsczeck, C., and Schmalz, G. (2010). Transcriptomes and proteomes of dental follicle cells. J. Dent. Res. 89, 445–456. doi: 10.1177/002203451036899

Mundy, G. R. (2007). Osteoporosis and inflammation. Nutr. Rev. 65(11 Pt 2), S147–S151

Pacifi, R. (2008). Estrogen deficiency, T cells and bone loss. Cell Immunol 252, 68–80.

Papapou, N. P., Wennstrom, J. L., and Grondahl, K. (1989). A 10-year retrospective study of periodontal disease progression. J. Clin. Periodontol. 16, 403–411. doi: 10.1111/j.1600-051x.1989.tb01668.x

Sonomaya, W., Liu, Y., Fang, D., Yamaza, T., Seo, B. M., Zhang, C., et al. (2006). Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One 1:e79. doi: 10.1371/journal.pone.000079

Sonomaya, W., Liu, Y., Yamaza, T., Tuan, R. S., Wang, S., Shi, S., et al. (2008). Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. J. Endod. 34, 166–171. doi: 10.1016/j.joen.2007.11.021

Soysa, N. S., and Alles, N. (2016). Osteoclast function and bone-resorbing activity: an overview. Biochim. Biophys. Res. Commun 476, 115–120. doi: 10.1016/j.bbrc.2016.05.019

Turecek, C., Fritzal-Zelman, N., Rumpler, M., Buchinger, B., Spitzer, S., Zoehrer, R., et al. (2008). Collagen cross-linking influences osteoblast differentiation. Calcif Tissue Int. 82, 392–400. doi: 10.1007/s00223-008-9136-3

Usha, P. R., and Naidu, M. U. (2004). Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin. Drug Invest. 24, 353–363. doi: 10.1016/j.clinph.2007.11.021

Verver, J. A., Jansen, I. D., Marthi, M., Coxon, F. P., McKenna, C. E., Sun, S., et al. (2013). Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors. Bone 57, 242–251. doi: 10.1016/j.bone.2013.08.007

Weitzmann, M. N., and Pacifi, R. (2006). Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116, 1186–1194.

Willingham, M. D., Brodt, M. D., Lee, K. L., Stephens, A. L., Ye, J., and Silva, M. J. (2010). Age-related changes in bone structure and strength in female and male BALB/c mice. Calcif. Tissue Int. 87, 470–483. doi: 10.1007/s00223-010-9359-y

Author Disclaimer: Solely the authors’ responsibility and does not necessarily represent the official views of National Institutes of Health.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Aljohani, Senbanjo, Al Qraee, Stains and Chellaiia. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.